Compare EPAM Systems Inc (EPAM) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Philip Morris International Inc. — how do they compare? EPAM Systems Inc trades at $113.91 (market cap $5.87B), while Philip Morris International Inc. trades at $199.93 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 53.2× EPAM Systems Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Philip Morris International Inc. for 85 Days on average.
| EPAM | PM | |
|---|---|---|
Market Cap | $5.87B | $312.50B |
Volume | 847,420 | 5,517,172 |
Sector | Technology | Consumer Staples |
52-Week High | $221.40 | $200.50 |
52-Week Low | $76.04 | $144.33 |
Typical Hold Time | 37 Days | 85 Days |
Enterprise Value | $5.24B | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM trades at $108.32, down 0.91% on the day, with a bearish technical signal but solid fundamentals including a P/E of 15.45 and three consecutive quarterly EPS beats. Revenue grew to $5.46B in 2025, though net income margin compressed to 6.92%. Recent news highlights AI-native revenue growth exceeding 11% and activist investor Engine Capital urging a $750M share buyback.
The stock appears undervalued with a consensus price target of $119, offering ~10% upside, but faces near-term headwinds from slower North American growth and AI disruption to legacy services. Investor sentiment is mixed, balancing strong analyst support (59% buy ratings) against technical weakness and competitive pressures.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
